Overview

Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (HBV). We are developing a portfolio of proprietary drug candidates with multiple mechanisms of action that we believe will result in a safe and effective combination therapy to cure HBV. Arbutus' comprehensive HBV pipeline of drugs and drug candidates optimally positions us to transform the HBV treatment landscape and to capitalize on the global market opportunity represented by the significant unmet medical need and large global prevalence of HBV. We will advance our assets and combine them as quickly as possible to bring superior treatment options to patients.

 

We have assembled a team with significant expertise and a proven track record in discovering and developing drug candidates targeting liver diseases, including hepatitis C. We are applying the same innovative thinking to our HBV programs that members of our management team have successfully applied to developing the hepatitis C cure Sovaldi® − the most successful drug launch in history.

 

In addition to our robust HBV pipeline and proven management team, we have a strong financial position that is further supported by our equity investment in Genevant Sciences and our royalty entitlement on Alnylam’s ONPATTRO™ (patisiran), approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hereditary ATTR amyloidosis with polyneuropathy -- ONPATTRO is enabled by our Lipid Nanoparticle (LNP) delivery technology.

 

We have licensed our Lipid Nanoparticle (LNP) and ligand conjugate delivery technologies to several industry partners, allowing us to focus in one therapeutic area - HBV. Our partnered delivery technologies have been proven in RNA interference (RNAi) therapeutic development and represent opportunity in all applications of nucleic acid delivery to the liver.  We see significant value in the collaborations Arbutus has established to date, and will continue to work closely with, and support, our partners.